Although renal cell carcinoma remains a difficult-to-treat disease, with patients with clear cell histology experiencing a median overall survival of approximately 13 months and a 5-year overall survival rate of less than 10%, updated results from clinical trials examining emerging therapeutic strategies have spurred optimism.